Search for: [Abstract = "Rheumatoid arthritis \(RA\) and psoriatic arthritis \(PsA\) are the two most common chronic rheumatic inflammatory diseases. Biological disease\-modifying drugs \(bDMARDs\), initially the original ones, and then also their biosimilar equivalents significantly increased the number of patients with RA and PsA achieving both remission and low disease activity. It was observed that the effects of bDMARDs in the so\-called real\-world evidence \(RWE\) differ from those recorded in randomized clinical trials, so there is a need to acquire and analyze RWE data. Data from long\-term observations of patients treated in RWE are relatively scarce, both in relation to bDMARDs in PsA and to some bDMARDs, especially rituximab \(RTX\), in RA. So far, no RWE data on the effectiveness of biosimilar RTX, GP2013 in RA have been published. Moreover, the methods of defining remission and low disease activity in both RA and PsA remains an important and unresolved problem. Since no uniform and universally accepted definition of these concepts has been adopted, the percentage of patients achieving remission and low disease activity remains dependent on the indicators used, and therefore the discrepancies reported in the literature are significant. The aim of this study was\: 1. to explore drug effectiveness, drug survival and reasons for discontinuing therapy for RTX and its biosimilar, GP2013, in pat"]
